Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.
| Website: | www.pieris.com |
| Email: | kelman@pieris.com |
| Main Phone: | +1 857 246-8998 |
| Address: | 255 State Street |
| Address 2: | 9th floor |
| State: | MA |
| City / Town: | Boston |
| Country: | USA |
| Postal Code: | 02109 |
| Exchange: | NSC |
| CEO: | Stephen S. Yoder |
| Employees: | 116 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A technical view of four stocks that appear to be at or near a breakout point.
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
Collaboration on 3 immuno-oncology programs
Is this group ready to reverse course?
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.
| Website: | www.pieris.com |
| Email: | kelman@pieris.com |
| Main Phone: | +1 857 246-8998 |
| Address: | 255 State Street |
| Address 2: | 9th floor |
| State: | MA |
| City / Town: | Boston |
| Country: | USA |
| Postal Code: | 02109 |
| Exchange: | NSC |
| CEO: | Stephen S. Yoder |
| Employees: | 116 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A technical view of four stocks that appear to be at or near a breakout point.
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
Collaboration on 3 immuno-oncology programs
Is this group ready to reverse course?
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
| Last Price 3.31 | Change $ -0.04 | Change % -1.19 | Tick N/A |
| Bid 3.11 | Bid Size 500.00 | Ask 3.34 | Ask Size 1,000.00 |
| Open 3.39 | High 3.42 | Low 3.23 | Prev Close 3.35 |
| Last Trade | Volume 280,656 | 52 Wk Hi 6.04 | 52 Wk Low 2.45 |
| Market Cap 182 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 54,975,666.00 | EPS (TTM) -0.70 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 5 |
| Number of Buys | 1 | 5 |
| Number of Sells | 0 | 0 |
| Net Activity | 10000 | 535000 |
| Last 10 Buys | Shares |
|---|---|
| James A. Geraghty | 1,000 |
| Allan Reine | 1,000 |
| James A. Geraghty | 1,000 |
| Allan Reine | 1,000 |
| Louis Matis | 1,000 |
| Darlene M. Deptula-Hicks | 1,000 |
| Louis Matis | 1,000 |
| Stephen S. Yoder | 1,000 |
| Chau Q. Khuong | 1,000 |
| Chau Q. Khuong | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| N/A | 0 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 13 | 13 | 13 | 13 |
| Low Target Price Estimate | 8 | 8 | 8 | 8 |
| Mean Target Price Estimate | 11.25 | 11.25 | 11.25 | 11.25 |
| Standard Deviation | 2.22 | 2.22 | 2.22 | 2.22 |
| Date of Most Recent Estimate | 05/14/18 | 05/14/18 | 05/14/18 | 05/14/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| DEFA14A | Additional proxy soliciting materials - definitive | 2 | 2018-06-14 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 74 | 2018-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 25 | 2018-06-06 |
| SC 13D/A | Amendment to a SC 13D filing | 10 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 231 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 10 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 29 | 2018-05-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| SC 13D/A | Amendment to a SC 13D filing | 10 | 2018-05-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait